Brief: Dong-A ST Demonstrates Therapeutic Equivalence Between DMB-3115 And Stelara In Global Phase III
17/01/2023 14:27
Jan 17 (Reuters) - Dong-A ST Co Ltd 170900.KS :
* DONG-A ST DEMONSTRATES THERAPEUTIC EQUIVALENCE BETWEEN
DMB-3115
AND STELARA IN GLOBAL PHASE III
* DONG-A ST-GLOBAL PHASE III WITH 605 PATIENTS FROM U.S. & 8
EUROPEAN COUNTRIES DEMONSTRATES THERAPEUTIC EQUIVALENCE & SAFETY
BETWEEN STELARA &DMB-3115
* DONG-A ST CO LTD - AIMS TO SUBMIT MARKETING AUTHORIZATION
IN
FIRST HALF OF 2023 FOR US AND EU
Source text for Eikon: ID:nBwbp0Pb0a
Further company coverage: 170900.KS
Recent news on Dong-A ST
See all newsBrief: Dong-A St Q1 Operating Profit 10.8 Billion Won, Up 53.7% From Year Earlier
Brief: Dong-A St To Cancel 5 Billion Won Worth Of Own Shares
Brief: Dong-A St Q4 Operating Loss 554 Million Won
Brief: Dong-A St Q2 Operating Profit 4 Billion Won, Down 43.4% From Year Earlier
Brief: Dong-A St Q1 Operating Profit 7 Billion Won, Up 854% From Year Earlier